Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024902

CHIEF SCIENTIFIC OFFICER sold 10,229 shares at an average $27.54 ($281,664)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-10-04 Sale 10b5-1 −7,522 $27.51 $206,937 1,069,887 I
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-10-07 Sale 10b5-1 −2,707 $27.61 $74,727 1,067,180 I
Open-market sales · 10,229 sh · avg $27.54 · $281,664
Loading xslF345X05/form4-10082024_101021.xml…